InMode Authorizes 10% Share Buyback Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy INMD?
Source: Benzinga
- Share Buyback Program: InMode's Board has authorized a new share repurchase program for up to 10% of its outstanding shares, approximately 6.38 million shares, reflecting the company's commitment to returning value to shareholders despite challenging economic conditions.
- Strong Cash Flow: Despite macroeconomic challenges, InMode continues to generate robust cash flow, with management believing that repurchasing shares at current valuations is an attractive use of capital aimed at enhancing shareholder value.
- Price Trend Analysis: Currently, InMode's stock is trading 7.4% below its 50-day simple moving average and 8% below its 200-day moving average, with a 30.88% decline over the past 12 months, indicating market caution regarding its future performance.
- Financial Expectations: InMode is expected to report earnings of $0.37 per share and revenue of $79.32 million in its upcoming financial update on April 27, 2026, showing year-over-year growth, although analysts maintain a hold rating with price targets ranging from $15 to $25.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INMD
Wall Street analysts forecast INMD stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 14.400
Low
15.00
Averages
17.33
High
21.00
Current: 14.400
Low
15.00
Averages
17.33
High
21.00
About INMD
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Announcement: InMode (INMD) is set to release its Q1 2023 earnings report on May 6 before market open, with consensus EPS estimated at $0.30, reflecting a 3.2% year-over-year decline, while revenue is projected at $79.86 million, indicating a 2.5% year-over-year increase.
- Performance Forecast: Over the past two years, InMode has exceeded EPS and revenue estimates 63% of the time, demonstrating a degree of stability in financial performance, although recent estimates show no upward revisions.
- Revision Trends: In the last three months, EPS estimates have seen five downward revisions with no upward adjustments, and revenue estimates have also faced three downward revisions, suggesting a cautious market outlook on the company's future performance.
- Repurchase Program: InMode has recently initiated a new share repurchase program aimed at enhancing shareholder value, despite the market's lingering doubts about its growth prospects.
See More
- Revenue Growth: InMode's Q1 2026 GAAP revenues reached $82 million, reflecting a 5% year-over-year increase, indicating the company's ability to maintain stable growth even in a challenging macroeconomic environment, which enhances market confidence.
- Margin Decline: Despite the revenue increase, GAAP gross margin fell from 78% in 2025 to 75% in Q1 2026, primarily due to rising costs, which could impact future profitability and investor sentiment.
- Shareholder Returns: As of March 31, 2026, InMode repurchased 2.55 million ordinary shares, returning $34.8 million to shareholders, demonstrating a proactive approach to capital allocation that helps enhance shareholder value.
- Executive Changes: CFO Yair Malca has stepped down and will serve as a consultant, while Board Chair Dr. Michael Anghel has resigned, indicating potential shifts in the company's strategic direction and market response.
See More
- Earnings Highlights: InMode reported its Q1 2026 earnings with a non-GAAP EPS of $0.25, missing estimates by $0.05, while revenue reached $82 million, a 5.3% year-over-year increase, beating expectations by $2.14 million, indicating stability in the market.
- Consumables and Services Revenue: The revenue from consumables and services was $21.4 million, reflecting a 6% increase compared to Q1 2025, demonstrating ongoing growth in core business areas and enhancing the company's competitive position.
- Cash Position: As of March 31, 2026, InMode's total cash position, including cash and cash equivalents, marketable securities, and short-term bank deposits, stood at $537.2 million, ensuring financial flexibility for future investments and operations.
- Share Repurchase Program: The company completed the repurchase of 2.55 million ordinary shares, returning $34.8 million to shareholders, with $3.6 million paid in Q2 2026, reflecting a commitment to shareholder returns and confidence in future growth prospects.
See More
- Conference Details: InMode Ltd.'s CEO Moshe Mizrahy and CFO Yair Malca will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, showcasing the company's innovations in medical technology.
- Investor Engagement: The event will feature virtual one-on-one meetings with investors, allowing for enhanced interaction and transparency by enabling investors to schedule meetings through their Needham representatives.
- Technological Focus: InMode specializes in developing and marketing devices that utilize novel radiofrequency technology across various fields, including plastic surgery, gynecology, and dermatology, aiming to drive new surgical procedures and improve existing treatments.
- Forward-Looking Statements: The company cautions that actual financial or operational performance may differ from expectations, urging investors to consider risk factors and cautionary statements to avoid undue reliance on forward-looking statements.
See More
- Conference Details: InMode's CEO Moshe Mizrahy and CFO Yair Malca will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, showcasing the company's latest medical technologies and market strategies, which is expected to attract investor interest.
- Investor Engagement: On the same day, InMode will also hold virtual one-on-one investor meetings, providing opportunities for direct interaction with company executives, aimed at enhancing investor relations and fostering potential investment collaborations.
- Technological Innovation: InMode focuses on developing and manufacturing innovative medical devices that leverage novel radiofrequency technology, committed to enabling emerging surgical procedures and improving existing treatments, demonstrating the company's leadership in the medical technology sector.
- Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future financial and operational performance, cautioning investors about potential risks and uncertainties to better assess their investment decisions.
See More
- Share Buyback Program: InMode's Board has authorized a new share repurchase program for up to 10% of its outstanding shares, approximately 6.38 million shares, reflecting the company's commitment to returning value to shareholders despite challenging economic conditions.
- Strong Cash Flow: Despite macroeconomic challenges, InMode continues to generate robust cash flow, with management believing that repurchasing shares at current valuations is an attractive use of capital aimed at enhancing shareholder value.
- Price Trend Analysis: Currently, InMode's stock is trading 7.4% below its 50-day simple moving average and 8% below its 200-day moving average, with a 30.88% decline over the past 12 months, indicating market caution regarding its future performance.
- Financial Expectations: InMode is expected to report earnings of $0.37 per share and revenue of $79.32 million in its upcoming financial update on April 27, 2026, showing year-over-year growth, although analysts maintain a hold rating with price targets ranging from $15 to $25.
See More










